Pioneering Anti-Fibrotic Therapeutics
DUB Therapeutics is developing breakthrough self-delivering RNA therapeutics to address fibrosis—starting with critical unmet needs in ocular surface diseases.
Innovative Delivery
Self-delivering siRNA technology that penetrates cells without additional carriers, offering non-invasive topical treatment.
Proven Science
Backed by rigorous research and $3M+ in funding from NIH and Upstate Biotech Venture, with patent protection in key markets.
Patient-Focused
Single-dose treatment lasting weeks, room temperature stable, dramatically improving patient compliance and outcomes.
Revolutionary sdRNA Platform
Our proprietary anti-fibrotic self-delivering siRNA, sdRNA, technology addresses the critical limitations of current ocular therapeutics.
Non-Invasive Topical Delivery
No injection required. Formulated as liquid therapeutic droplets for easy administration.
Single-Dose Treatment
Modifications promote pharmaceutical benefit for >90 days in vivo, eliminating frequent dosing.
Room Temperature Stable
Solution stable at RT for >360 days
Self-Delivering sdRNA
AAV and lipid nanoparticle free delivery
DUB Therapeutics vs. Current Standard of Care
| Feature | DUB Tx | Steroids | NGF Therapy | Transplant |
|---|---|---|---|---|
| Topical Delivery | N/A | |||
| Effective Treatment | Mixed | |||
| Dosing Frequency | One dose | 6+/day | 6+/day | N/A |
| Affordable | ~$85k | High cost | ||
| Accessible | Limited | Limited |
Development Pipeline
Advancing multiple therapeutic programs across ophthalmology, dermatology, and systemic fibrosis. Our self-delivering RNA platform targets tissue scarring at its source.
Persistent Corneal Epithelial Defect (PCED)
Primary indication targeting corneal wound healing and scarring prevention.
Glaucoma Surgery Scarring
Secondary indication for preventing scarring post-glaucoma surgery.
Market Opportunity
The global ophthalmic market is projected to reach $65B by 2030, with over 2.2B⁺people affected by vision impairment or blindness worldwide.
- •12.5M+ patients with corneal diseases
- •50+ addressable disease indications
- •Expanding to posterior segment applications
Join Us in Transforming Vision Care
Whether you're an investor, partner, or simply interested in our mission, we'd love to hear from you.
Subscribe to Our Newsletter
Get the latest updates on our research, clinical trials, and company news.